The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
adenovirus-transfected DC vaccine plus CIK cells
Department of Hematopoietic Stem Cell Transplantation
Beijing, China
objective tumor response (CR+PR) as measured by RECIST criteria
Time frame: 4 weeks after DC/CIK treatment
number of participants with adverse events
Time frame: 3 days within DC/CIK treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.